The Multiple Myeloma CAR-T segment shows robust expansion, with the US market estimated at $400 million in 2022 and expected ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

Group14 raises $463 million, South Korea to restructure petrochemicals, AbbVie buys rights to bretisilocin, and more ...

Kite Pharma will buy Interius BioTherapeutics for $350 million in cash to add an in vivo CAR‑T platform that creates T‑cell ...

Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

Kite, a Gilead Company, has announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

A Philadelphia biotech startup's promising approach to cancer therapy is about to get the firm acquired by a major player in ...

Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...